SCHEMBL23879544

SCHEMBL23879544

C=C(CCNC(=O)c1ccc(C(F)(F)F)cc1NS(=O)(=O)c1ccc(S(=O)(=O)C(F)F)cc1)C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.49
▸ ACLY P53396 2/20 0.47
▸ USP2 O75604 4/20 0.44
▸ USP8 P40818 4/20 0.44
▸ USP36 Q9P275 1/20 0.43
▸ FLT1 P17948 2/20 0.42
▸ FLT4 P35916 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ MCL1 Q07820 1/20 0.41
▸ KCNA5 P22460 1/20 0.41
▸ GPR27 Q9NS67 3/20 0.41
▸ AVPR2 P30518 2/20 0.41
▸ CCR1 P32246 1/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ DNMT1 P26358 1/20 0.40
▸ CASP6 P55212 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CCR9 P51686 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24268165 0.90 KDM1A (0.51) KDM1AACLYUSP2USP8USP36
SCHEMBL23879571 0.89 KDM1A (0.50) KDM1AACLYUSP2USP8USP36
SCHEMBL23879629 0.89 KDM1A (0.50) KDM1AACLYUSP2USP8USP36
SCHEMBL23879530 0.89 ACLY (0.52) KDM1AACLYUSP2USP8USP36
SCHEMBL24268128 0.89 KDM1A (0.49) KDM1AACLYUSP2USP8USP36
SCHEMBL23879568 0.88 USP2 (0.47) KDM1AACLYUSP2USP8USP36
SCHEMBL24268146 0.87 KDM1A (0.48) KDM1AACLYUSP2USP8USP36
SCHEMBL24268109 0.87 KDM1A (0.48) KDM1AACLYUSP2USP8USP36
SCHEMBL23879609 0.87 KDM1A (0.48) KDM1AACLYUSP2USP8USP36
SCHEMBL23879577 0.85 KDM1A (0.46) KDM1AACLYUSP2USP8USP36

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B KDM1A 2735/4885ACLY 2228/4885USP2 3178/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B KDM1A 2735/4885ACLY 2228/4885USP2 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback